Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to -$2.7 million.

  • Marker Therapeutics' Cash from Operations fell 32846.58% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.8 million, marking a year-over-year decrease of 7279.89%. This contributed to the annual value of -$10.9 million for FY2024, which is 3363.53% up from last year.
  • Marker Therapeutics' Cash from Operations amounted to -$2.7 million in Q3 2025, which was down 32846.58% from -$1.9 million recorded in Q2 2025.
  • Marker Therapeutics' 5-year Cash from Operations high stood at $1.2 million for Q3 2024, and its period low was -$12.2 million during Q1 2022.
  • For the 5-year period, Marker Therapeutics' Cash from Operations averaged around -$4.8 million, with its median value being -$4.9 million (2021).
  • In the last 5 years, Marker Therapeutics' Cash from Operations crashed by 78795.39% in 2023 and then skyrocketed by 20621.22% in 2024.
  • Quarter analysis of 5 years shows Marker Therapeutics' Cash from Operations stood at -$4.9 million in 2021, then decreased by 29.79% to -$6.3 million in 2022, then soared by 62.45% to -$2.4 million in 2023, then crashed by 98.65% to -$4.7 million in 2024, then soared by 41.83% to -$2.7 million in 2025.
  • Its Cash from Operations was -$2.7 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$5.5 million in Q1 2025.